Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited.
This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.
Adults aged 18 to 100 years.
A histologically confirmed diagnosis of hepatocellular carcinoma.
A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.
Healthy volunteers without known liver disease or malignancy.
Lack of or inability to provide informed consent
History of other active malignancies within the past 5 years
Previous liver transplantation
Severe systemic infection or inflammatory disease at the time of enrollment